-
Plenary III Features Highly Rated Scientific Abstracts Across Diverse Topics
In Tuesday’s plenary session, investigators, including Joshua Baker, MD, MSCE, presented new data on a lifestyle intervention trial for rheumatoid arthritis, the first head-to-head trial looking at a primary joint endpoint in psoriatic arthritis, longitudinal risk stratification in pulmonary sarcoidosis, disease prediction models, infliximab biosimilar switching, and treatment targets for modified disease activity scores.
More news from #ACR26
-
FDA Gives Updates on Newly Approved Agents for Rheumatic Diseases
Jeong Min Yu, MD, MS, and other medical officers from the U.S. Food and Drug Administration discussed approvals including a Janus kinase and tyrosine kinase 2 inhibitor for dermatomyositis and an interleukin-23 antagonist for psoriatic arthritis, both for the treatment of adults.
-
ARP Distinguished Lecture Shares Step-by-Step Strategy for Living with Fibromyalgia
Christine Stamatos, DNP, ANP-C, outlined a fibromyalgia “toolbox” designed for the implementation of evidence-based treatment approaches. “We have to educate patients and help them understand what they have control over,” she said.
ACR Convergence Newsmakers
-
Panel to Show How Social Determinants of Health Drive Outcomes in Rheumatic Disease
S. Sam Lim, MD, MPH, and other experts will illustrate how rheumatology professionals can make the field more precise, more rigorous, and more equitable by recognizing the intertwined relationship between social and structural context and disease management.
-
Learn from Patients During a Wednesday Morning Session
Sarah B. Lieber, MD, MS, will moderate a session focused on how three individuals and their care teams have personalized the management of their rheumatic disease to the patients’ benefit. The presenters will explain how their experiences have been leveraged to create resources and strategies for the larger rheumatology community.
-
Hormone Therapy During Menopause Could Have a Role for Some Patients with Rheumatic Diseases
Stephanie Faubion, MD, MBA, and Karen Costenbader, MD, MPH, reviewed new evidence about the value of hormone therapy for patients with autoimmune disease in menopause and post menopause.
Presenter Spotlights
